Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and
Blood After Oral Administration of Medical Cannabis With
Respect to its Effect on Driving Abilities

J 2022

Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ et. al.

Basic information

Original name

Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities

Authors

TROJAN, Vaclav (203 Czech Republic, guarantor), Leoš LANDA (203 Czech Republic, belonging to the institution), Radovan HRIB (203 Czech Republic), Jan JUŘICA (203 Czech Republic, belonging to the institution), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), Vaclav ZVONICEK (203 Czech Republic), Lenka HALAMKOVA (203 Czech Republic), Jan HALAMEK (203 Czech Republic), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Silvie BĚLAŠKOVÁ (203 Czech Republic, belonging to the institution) and Jiri SLIVA (203 Czech Republic)

Edition

Physiological Research, Praha, Akademie Ved Ceske Republiky, 2022, 0862-8408

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.100

RIV identification code

RIV/00216224:14110/22:00127231

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.33549/physiolres.934907

UT WoS

000892128700007

Keywords (in Czech)

Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment

Keywords in English

Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment

Abstract

V originále

Summary Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydrocannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ, Vaclav ZVONICEK, Lenka HALAMKOVA, Jan HALAMEK, Regina DEMLOVÁ, Silvie BĚLAŠKOVÁ and Jiri SLIVA. Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities. Physiological Research. Praha: Akademie Ved Ceske Republiky, 2022, vol. 71, No 5, p. 703-712. ISSN 0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934907.

@article{2233719,
   author = {Trojan, Vaclav and Landa, Leoš and Hrib, Radovan and Juřica, Jan and Rychlíčková, Jitka and Zvonicek, Vaclav and Halamkova, Lenka and Halamek, Jan and Demlová, Regina and Bělašková, Silvie and Sliva, Jiri},
   article_location = {Praha},
   article_number = {5},
   doi = {http://dx.doi.org/10.33549/physiolres.934907},
   keywords = {Delta-9-tetrahydrocannabinol; Cannabis; Driving abilities; Chronic pain treatment},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological Research},
   title = {Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities},
   url = {https://www.biomed.cas.cz/physiolres/pdf/2022/71_703.pdf},
   volume = {71},
   year = {2022}
}

TY  - JOUR
ID  - 2233719
AU  - Trojan, Vaclav - Landa, Leoš - Hrib, Radovan - Juřica, Jan - Rychlíčková, Jitka - Zvonicek, Vaclav - Halamkova, Lenka - Halamek, Jan - Demlová, Regina - Bělašková, Silvie - Sliva, Jiri
PY  - 2022
TI  - Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities
JF  - Physiological Research
VL  - 71
IS  - 5
SP  - 703-712
EP  - 703-712
PB  - Akademie Ved Ceske Republiky
SN  - 08628408
KW  - Delta-9-tetrahydrocannabinol
KW  - Cannabis
KW  - Driving abilities
KW  - Chronic pain treatment
UR  - https://www.biomed.cas.cz/physiolres/pdf/2022/71_703.pdf
N2  - Summary Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydrocannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.
ER  -

TROJAN, Vaclav, Leoš LANDA, Radovan HRIB, Jan JUŘICA, Jitka RYCHLÍČKOVÁ, Vaclav ZVONICEK, Lenka HALAMKOVA, Jan HALAMEK, Regina DEMLOVÁ, Silvie BĚLAŠKOVÁ and Jiri SLIVA. Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities. \textit{Physiological Research}. Praha: Akademie Ved Ceske Republiky, 2022, vol.~71, No~5, p.~703-712. ISSN~0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934907.

Detailed Information on Publication Record